|
ATE190355T1
(de)
|
1988-09-06 |
2000-03-15 |
Xoma Corp |
Genexpressions-elemente und herstellung von chimären maus-mensch-antikörpern
|
|
IL89490A0
(en)
*
|
1988-11-17 |
1989-09-10 |
Hybritech Inc |
Chimeric antibodies directed against metal chelates
|
|
WO1991006649A1
(en)
*
|
1989-11-07 |
1991-05-16 |
The Green Cross Corporation |
Mouse antibody v-region gene fragment and preparation of chimera antibody by using said gene fragment
|
|
GB9022543D0
(en)
*
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Antibody production
|
|
WO1992013077A1
(en)
*
|
1991-01-29 |
1992-08-06 |
Brigham And Women's Hospital |
A cDNA ENCODING THE TYPE I IODOTHYRONINE 5' DEIODINASE
|
|
US5272078A
(en)
*
|
1991-01-29 |
1993-12-21 |
Brigham And Women's Hospital |
CDNA encoding the type I iodothyronine 5'deiodinase
|
|
US20050196400A1
(en)
*
|
1991-05-06 |
2005-09-08 |
Xoma Technology Ltd. |
Production of chimeric mouse-human antibodies with specificity to human tumor antigens
|
|
US5756096A
(en)
*
|
1991-07-25 |
1998-05-26 |
Idec Pharmaceuticals Corporation |
Recombinant antibodies for human therapy
|
|
IE922437A1
(en)
*
|
1991-07-25 |
1993-01-27 |
Idec Pharma Corp |
Recombinant antibodies for human therapy
|
|
US6136310A
(en)
|
1991-07-25 |
2000-10-24 |
Idec Pharmaceuticals Corporation |
Recombinant anti-CD4 antibodies for human therapy
|
|
US6004555A
(en)
*
|
1992-03-05 |
1999-12-21 |
Board Of Regents, The University Of Texas System |
Methods for the specific coagulation of vasculature
|
|
US6093399A
(en)
*
|
1992-03-05 |
2000-07-25 |
Board Of Regents, The University Of Texas System |
Methods and compositions for the specific coagulation of vasculature
|
|
US6749853B1
(en)
|
1992-03-05 |
2004-06-15 |
Board Of Regents, The University Of Texas System |
Combined methods and compositions for coagulation and tumor treatment
|
|
US6036955A
(en)
*
|
1992-03-05 |
2000-03-14 |
The Scripps Research Institute |
Kits and methods for the specific coagulation of vasculature
|
|
US5877289A
(en)
*
|
1992-03-05 |
1999-03-02 |
The Scripps Research Institute |
Tissue factor compositions and ligands for the specific coagulation of vasculature
|
|
FR2724320B1
(fr)
*
|
1994-09-13 |
1996-12-20 |
Transgene Sa |
Nouvel implant pour le traitement des maladies acquises
|
|
US6001358A
(en)
*
|
1995-11-07 |
1999-12-14 |
Idec Pharmaceuticals Corporation |
Humanized antibodies to human gp39, compositions containing thereof
|
|
US6440418B1
(en)
|
1995-11-07 |
2002-08-27 |
Idec Pharmaceuticals Corporation |
Methods of treating autoimmune diseases with gp39-specific antibodies
|
|
EP0909277B2
(en)
*
|
1996-06-07 |
2008-12-24 |
Poniard Pharmaceuticals, Inc. |
Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
|
|
US6420140B1
(en)
*
|
1996-10-11 |
2002-07-16 |
Abgenix, Inc. |
Production of multimeric protein by cell fusion method
|
|
US5916771A
(en)
|
1996-10-11 |
1999-06-29 |
Abgenix, Inc. |
Production of a multimeric protein by cell fusion method
|
|
US6348581B1
(en)
|
1996-10-31 |
2002-02-19 |
The Dow Chemical Company |
High affinity humanized anti-TAG-72 monoclonalantibodies
|
|
DK0966533T3
(da)
|
1997-02-07 |
2010-01-04 |
Us Gov Health & Human Serv |
Aktivitetsafhængig neurotrof faktor III (ADNF III).
|
|
US7033589B1
(en)
|
1997-02-20 |
2006-04-25 |
Biogen Idec Ma Inc. |
γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
|
|
US6893636B2
(en)
*
|
1997-02-20 |
2005-05-17 |
Biogen Idec Ma Inc. |
Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
|
|
US7147854B2
(en)
*
|
1997-06-23 |
2006-12-12 |
Yes Biotech Laboratories Ltd. |
Topical treatment of psoriasis using neutralizing antibodies to interleukin-8
|
|
DE69824039T2
(de)
*
|
1997-12-08 |
2005-08-18 |
Lexigen Pharmaceuticals Corp., Lexington |
Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
|
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
|
RU2244547C2
(ru)
|
1998-05-19 |
2005-01-20 |
Рисерч Дивелопмент Фаундейшн |
Тритерпеновые композиции и способы их применения
|
|
AU6162999A
(en)
*
|
1998-09-24 |
2000-04-10 |
Promega Corporation |
Apoptosis marker antibodies and methods of use
|
|
US20020102208A1
(en)
|
1999-03-01 |
2002-08-01 |
Paul Chinn |
Radiolabeling kit and binding assay
|
|
US20030143233A1
(en)
*
|
1999-06-07 |
2003-07-31 |
Neorx Corporation |
Streptavidin expressed gene fusions and methods of use thereof
|
|
US7144991B2
(en)
|
1999-06-07 |
2006-12-05 |
Aletheon Pharmaceuticals, Inc. |
Streptavidin expressed gene fusions and methods of use thereof
|
|
US20030103948A1
(en)
*
|
1999-06-07 |
2003-06-05 |
Neorx Corporation |
Streptavidin expressed gene fusions and methods of use thereof
|
|
EP1731531B1
(en)
|
1999-08-09 |
2012-05-30 |
Merck Patent GmbH |
Multiple cytokine-antibody complexes
|
|
AU2154401A
(en)
|
1999-11-12 |
2001-05-30 |
Merck Patent Gmbh |
Erythropoietin forms with improved properties
|
|
WO2001058957A2
(en)
|
2000-02-11 |
2001-08-16 |
Lexigen Pharmaceuticals Corp. |
Enhancing the circulating half-life of antibody-based fusion proteins
|
|
WO2001094586A2
(en)
*
|
2000-06-06 |
2001-12-13 |
Idec Pharmaceuticals Corporation |
Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof
|
|
CA2412845C
(en)
|
2000-06-29 |
2014-07-22 |
Lexigen Pharmaceuticals Corp. |
Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
|
|
US20060148732A1
(en)
*
|
2000-11-17 |
2006-07-06 |
Gutterman Jordan U |
Inhibition of NF-kappaB by triterpene compositions
|
|
BR0207854A
(pt)
|
2001-03-07 |
2004-08-24 |
Merck Patent Gmbh |
Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido
|
|
US6992174B2
(en)
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
|
EP1383785B1
(en)
*
|
2001-05-03 |
2011-03-16 |
Merck Patent GmbH |
Recombinant tumor specific antibody and use thereof
|
|
US7399743B2
(en)
*
|
2001-10-26 |
2008-07-15 |
The Scripps Research Institute |
Targeted thrombosis
|
|
CN100390282C
(zh)
|
2001-12-04 |
2008-05-28 |
默克专利有限公司 |
具有调节的选择性的il-2融合蛋白
|
|
US7332585B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The California University |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
|
NZ574146A
(en)
|
2002-07-15 |
2010-05-28 |
Univ Texas |
Peptides binding to phosphatidylethanolamine and their use in treating viral infections
|
|
EP1572121B1
(en)
|
2002-08-01 |
2012-01-11 |
The Regents of The University of California |
Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
|
|
US20040053363A1
(en)
*
|
2002-09-18 |
2004-03-18 |
Thomas Ryll |
Method for production of a multimeric protein by cell fusion
|
|
US20040053359A1
(en)
*
|
2002-09-18 |
2004-03-18 |
Thomas Ryll |
Method for production of a multimeric protein by cell fusion
|
|
JP4033390B2
(ja)
*
|
2002-10-30 |
2008-01-16 |
独立行政法人科学技術振興機構 |
不死化ナチュラルキラー細胞株
|
|
DE60333121D1
(de)
|
2002-12-17 |
2010-08-05 |
Merck Patent Gmbh |
Pers 14.18, der gd2 bindet und seine fusion mit il-2
|
|
AU2004291107B2
(en)
|
2003-11-14 |
2010-09-30 |
Brigham And Women's Hospital, Inc. |
Methods of modulating immunity
|
|
CA2551916C
(en)
|
2003-12-31 |
2014-04-29 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
|
PL1706428T3
(pl)
|
2004-01-22 |
2010-02-26 |
Merck Patent Gmbh |
Przeciwciała przeciwnowotworowe o zredukowanym wiązaniu dopełniacza
|
|
US7700738B2
(en)
|
2005-01-27 |
2010-04-20 |
The Regents Of The University Of California |
Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
|
|
US9034345B2
(en)
|
2005-01-27 |
2015-05-19 |
Children's Hospital & Research Center Oakland |
GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
|
|
EP2270050B1
(en)
*
|
2005-12-30 |
2013-06-05 |
Merck Patent GmbH |
Anti-CD19 antibodies with reduced immunogenicity
|
|
EP2192922A4
(en)
|
2007-09-17 |
2010-09-29 |
Univ California |
INTERNATIONALIZING HUMAN MONOCLONAL ANTIBODIES TO PROMOTE IN SITU ON PROSTATAZELLES
|
|
EA034136B1
(ru)
|
2007-11-09 |
2020-01-09 |
Перигрин Фармасьютикалз, Инк. |
Изолированное антитело, которое связывается с vegf, и его применения
|
|
US10035834B2
(en)
|
2008-06-18 |
2018-07-31 |
The Texas A&M University System |
Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
|
|
WO2011088385A2
(en)
|
2010-01-15 |
2011-07-21 |
The Regents Of The University Of California |
Compositions and methods for detecting cancer
|
|
EP2525813B1
(en)
|
2010-01-20 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Anti-ilt5 antibodies and ilt5-binding antibody fragments
|
|
WO2011091181A1
(en)
|
2010-01-20 |
2011-07-28 |
Tolerx, Inc. |
Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
|
|
ME02670B
(me)
|
2010-03-26 |
2017-06-20 |
Memorial Sloan Kettering Cancer Center |
Antitela za MUC16 i metode za njihovu primenu
|
|
ES2571994T3
(es)
|
2010-04-09 |
2016-05-27 |
Critical Care Diagnostics Inc |
Anticuerpos contra ST-2 humana soluble y ensayos
|
|
KR20130066626A
(ko)
|
2010-04-29 |
2013-06-20 |
나스벡스 엘티디. |
항ｃｄ3 면역 분자 요법을 사용하여 간염을 치료하는 방법 및 이를 위한 조성물
|
|
CA2809363A1
(en)
|
2010-08-24 |
2012-03-01 |
Abbott Laboratories |
Hiv core protein specific antibodies and uses thereof
|
|
WO2012075173A2
(en)
|
2010-12-01 |
2012-06-07 |
Board Of Regents The University Of Texas System |
Compositions and method for deimmunization of proteins
|
|
WO2012118796A1
(en)
|
2011-02-28 |
2012-09-07 |
The Schepens Eye Research Institute, Inc. |
Compositions for controlling neuronal outgrowth
|
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
|
US9534059B2
(en)
|
2012-04-13 |
2017-01-03 |
Children's Medical Center Corporation |
TIKI inhibitors
|
|
WO2014093417A1
(en)
|
2012-12-12 |
2014-06-19 |
University Of Virginia Patent Foundation |
Compositions and methods for regulating erythropoiesis
|
|
EP2968550B1
(en)
|
2013-03-14 |
2018-11-14 |
Ffe Therapeutics LLC |
Compositions and methods for treating angiogenesis-related disorders
|
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
ES2941897T3
(es)
|
2014-11-12 |
2023-05-26 |
Seagen Inc |
Compuestos que interaccionan con glicanos y procedimientos de uso
|
|
CN107667120B
(zh)
|
2015-03-17 |
2022-03-08 |
纪念斯隆-凯特林癌症中心 |
抗muc16抗体及其应用
|
|
JP2018524588A
(ja)
|
2015-06-26 |
2018-08-30 |
ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド |
骨髄由来サプレッサー細胞中のテトラスパニン３３（Ｔｓｐａｎ３３）を標的化するがん療法
|
|
SG11201803213XA
(en)
|
2015-11-12 |
2018-05-30 |
Siamab Therapeutics Inc |
Glycan-interacting compounds and methods of use
|
|
ES2975747T3
(es)
|
2015-11-30 |
2024-07-12 |
Univ California |
Administración de carga útil específica de tumor y activación inmunitaria utilizando un anticuerpo humano que se dirige a un antígeno de superficie celular de tumor altamente específico
|
|
US12049511B2
(en)
|
2016-11-10 |
2024-07-30 |
Fortis Therapeutics, Inc. |
Engineered CD46-specific effector cells and uses thereof in the treatment of cancer
|
|
EP3541847A4
(en)
|
2016-11-17 |
2020-07-08 |
Seattle Genetics, Inc. |
COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
|
|
JP2020510671A
(ja)
|
2017-03-03 |
2020-04-09 |
シアトル ジェネティックス， インコーポレイテッド |
グリカン相互作用化合物および使用の方法
|
|
CN108727494A
(zh)
*
|
2017-04-25 |
2018-11-02 |
成都贝爱特生物科技有限公司 |
一种靶向筛选外源基因双整合位点提高人c5单抗表达产量的方法
|
|
EP3655031A1
(en)
|
2017-07-21 |
2020-05-27 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Neisseria meningitidis immunogenic compositions
|
|
US20200283537A1
(en)
|
2017-11-14 |
2020-09-10 |
University Of Virginia Patent Foundation |
Compositions and methods for making and using bispecific antibodies
|
|
TWI869346B
(zh)
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
|
|
IL317554A
(en)
|
2018-06-01 |
2025-02-01 |
Novartis Ag |
Anti-BCMA binding molecules and their uses
|
|
US20210355199A1
(en)
|
2018-06-28 |
2021-11-18 |
University Of Virginia Patent Foundation |
Compositions and methods for detecting and regulating fibronectin-integrin interaction and signaling
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
CN121293351A
(zh)
|
2019-05-21 |
2026-01-09 |
诺华股份有限公司 |
Cd19结合分子及其用途
|
|
EP3972993A1
(en)
|
2019-05-21 |
2022-03-30 |
Novartis AG |
Variant cd58 domains and uses thereof
|
|
US12384832B2
(en)
|
2019-06-19 |
2025-08-12 |
Christopher Oelkrug |
Antibody-mediated neutralization of beta-lactamases
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與ｅｎｔｐｄ２抗體之組合療法
|
|
WO2021053559A1
(en)
|
2019-09-18 |
2021-03-25 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
CN115151566A
(zh)
|
2019-11-15 |
2022-10-04 |
普利安特治疗公司 |
用于活化整合素的组合物和方法
|
|
JP2023517611A
(ja)
|
2020-03-10 |
2023-04-26 |
ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー |
Ｉｌ－６／ｉｌ－６ｒ抗体の組成物及びその使用方法
|
|
US20230190804A1
(en)
|
2020-06-17 |
2023-06-22 |
Tiziana Life Sciences Plc |
Compositions and methods for augmenting chimeric antigen receptor (car) t cell therapies
|
|
EP4188440A2
(en)
|
2020-07-30 |
2023-06-07 |
Tiziana Life Sciences PLC |
Cd-3 antibodies for the treatment of coronavirus
|
|
CN116419747B
(zh)
|
2020-08-07 |
2025-10-17 |
福蒂斯治疗公司 |
靶向cd46的免疫偶联物及其使用方法
|
|
IL302412A
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies
|
|
IL302569A
(en)
|
2020-11-06 |
2023-07-01 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
WO2022162569A1
(en)
|
2021-01-29 |
2022-08-04 |
Novartis Ag |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
|
BR112023021297A2
(pt)
|
2021-04-14 |
2023-12-12 |
Villaris Therapeutics Inc |
Anticorpos anti-cd122 e usos dos mesmos
|
|
US20220332822A1
(en)
|
2021-04-16 |
2022-10-20 |
Tiziana Life Sciences Plc |
Subcutaneous administration of antibodies for the treatment of disease
|
|
AU2022365121A1
(en)
|
2021-10-14 |
2024-04-18 |
The Brigham And Women's Hospital, Inc. |
Methods of suppressing microglial activation
|
|
US20230272082A1
(en)
|
2021-11-09 |
2023-08-31 |
Sensei Biotherapeutics, Inc. |
Anti-vista antibodies and uses thereof
|
|
WO2025006737A1
(en)
|
2023-06-30 |
2025-01-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Genetically detoxified mutant of neisseria and outer membrane vesicle (omv) vaccine
|
|
WO2025040820A1
(en)
|
2023-08-23 |
2025-02-27 |
Granular Therapeutics Limited |
Anti-cd203c antibody conjugates and uses thereof
|
|
WO2025215252A1
(en)
|
2024-04-12 |
2025-10-16 |
Ensocell Ltd |
Therapeutic agents and methods for targeting myeloid cell subtypes
|